Skip to main content

Table 2 Characteristics and outcomes of 7 patients with clinically significant infections

From: Persistence of related bla-IMP-4 metallo-beta-lactamase producing Enterobacteriaceae from clinical and environmental specimens within a burns unit in Australia - a six-year retrospective study

Patient No. Age and Sex Co-morbidities Isolate site (n = 11) Organism Treatment 30-day Mortality
1 62 M Nil CVC tip Klebsiella pneumoniae Amikacin 4 days Survived
2 61 M Alcohol abuse CVC tip Enterobacter cloacae Amikacin 14 days Survived
Blood Sputum Ciprofloxacin 14 days
3 36 M Alcohol abuse Wound Enterobacter cloacae Surgical wound debridement, with 1 dose amikacin at time of operation Survived
4 82 F COPD, PVD CVC tip Enterobacter cloacae Amikacin 5 days Survived*
5 62 M Nil Wound Enterobacter cloacae Amikacin 8 days, ciprofloxacin 7 days Survived
Wound Klebsiella pneumoniae
6 86 F Nil Wound Enterobacter cloacae Stat dose amikacin, ciprofloxacin 6 days Survived
7 92 M Nil known Blood Klebsiella pneumoniae Unknown Unknown
Urine
  1. * = died at 34 days after MBL infection, from respiratory failure related to inhalation injury, not attributed to MBL infection.